Overall survival in patients with myelodysplastic syndromes (MDS) according to receipt of ICT in a subgroup analysis. In this study, 18 patients receiving ICT were matched for baseline features to 18 controls with low or intermediate-1 IPSS risk MDS.
 Adapted from Leitch H, et al. Clinical Leukemia 2008;2:205–211, with permission from CIG Media Group, Danvers, USA.